Interleukin-3 Receptor alpha Subunit
"Interleukin-3 Receptor alpha Subunit" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A low affinity interleukin-3 receptor subunit that combines with the CYTOKINE RECEPTOR COMMON BETA SUBUNIT to form a high affinity receptor for INTERLEUKIN-3.
| Descriptor ID |
D053650
|
| MeSH Number(s) |
D12.776.543.750.705.852.420.340.500
|
| Concept/Terms |
Interleukin-3 Receptor alpha Subunit- Interleukin-3 Receptor alpha Subunit
- Interleukin 3 Receptor alpha Subunit
- Interleukin-3 Receptor alpha Chain
- Interleukin 3 Receptor alpha Chain
- Antigens, CD123
- CD123 Antigens
- alpha-Subunit, Receptor, Interleukin-3
- CD123 Antigen
- Antigen, CD123
|
Below are MeSH descriptors whose meaning is more general than "Interleukin-3 Receptor alpha Subunit".
Below are MeSH descriptors whose meaning is more specific than "Interleukin-3 Receptor alpha Subunit".
This graph shows the total number of publications written about "Interleukin-3 Receptor alpha Subunit" by people in this website by year, and whether "Interleukin-3 Receptor alpha Subunit" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2021 | 0 | 1 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Interleukin-3 Receptor alpha Subunit" by people in Profiles.
-
Improving the anti-acute myeloid leukemia activity of CD123-specific engager T cells by MyD88 and CD40 costimulation. Haematologica. 2023 04 01; 108(4):1039-1052.
-
Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy. Cytotherapy. 2022 03; 24(3):282-290.
-
CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia. Mol Ther. 2016 09 29; 24(9):1615-26.
-
CD123 Immunohistochemical Expression Is a Specific But Insensitive Marker of Early T-precursor Leukemia. Appl Immunohistochem Mol Morphol. 2016 Jan; 24(1):e4-5.
-
SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia. Br J Haematol. 2014 Sep; 166(6):862-74.
-
CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations. Appl Immunohistochem Mol Morphol. 2013 May; 21(3):212-7.
-
Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells. Protein Eng Des Sel. 2012 Oct; 25(10):561-9.
-
The value of immunohistochemistry for CD14, CD123, CD33, myeloperoxidase and CD68R in the diagnosis of acute and chronic myelomonocytic leukaemias. Histopathology. 2012 May; 60(6):933-42.
-
Association between interleukin-3 receptor alpha polymorphism and schizophrenia in the Chinese population. Neurosci Lett. 2008 Jul 25; 440(1):35-7.
-
Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients. Ann Surg Oncol. 2007 Oct; 14(10):2854-60.